| Product Code: ETC9627386 | Publication Date: Sep 2024 | Updated Date: Sep 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Taiwan Phosphodiesterase (PDE) Inhibitors Market Overview |
3.1 Taiwan Country Macro Economic Indicators |
3.2 Taiwan Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, 2021 & 2031F |
3.3 Taiwan Phosphodiesterase (PDE) Inhibitors Market - Industry Life Cycle |
3.4 Taiwan Phosphodiesterase (PDE) Inhibitors Market - Porter's Five Forces |
3.5 Taiwan Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume Share, By Types, 2021 & 2031F |
3.6 Taiwan Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.7 Taiwan Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 Taiwan Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.9 Taiwan Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Taiwan Phosphodiesterase (PDE) Inhibitors Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of erectile dysfunction and other related conditions in Taiwan |
4.2.2 Rising awareness and acceptance of phosphodiesterase (PDE) inhibitors among healthcare professionals and patients |
4.2.3 Growing geriatric population in Taiwan leading to higher demand for PDE inhibitors |
4.3 Market Restraints |
4.3.1 Stringent regulations and approval processes for new PDE inhibitor drugs in Taiwan |
4.3.2 Competition from alternative treatments such as herbal remedies and lifestyle changes |
5 Taiwan Phosphodiesterase (PDE) Inhibitors Market Trends |
6 Taiwan Phosphodiesterase (PDE) Inhibitors Market, By Types |
6.1 Taiwan Phosphodiesterase (PDE) Inhibitors Market, By Types |
6.1.1 Overview and Analysis |
6.1.2 Taiwan Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Types, 2021- 2031F |
6.1.3 Taiwan Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Specific, 2021- 2031F |
6.1.4 Taiwan Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Non-Specific, 2021- 2031F |
6.1.5 Taiwan Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Taiwan Phosphodiesterase (PDE) Inhibitors Market, By Indication |
6.2.1 Overview and Analysis |
6.2.2 Taiwan Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Congestive Heart Failure, 2021- 2031F |
6.2.3 Taiwan Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Erectile Dysfunction, 2021- 2031F |
6.2.4 Taiwan Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Inflammatory Airways Disease, 2021- 2031F |
6.2.5 Taiwan Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Taiwan Phosphodiesterase (PDE) Inhibitors Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 Taiwan Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 Taiwan Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.3.4 Taiwan Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Taiwan Phosphodiesterase (PDE) Inhibitors Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 Taiwan Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Taiwan Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Homecare, 2021- 2031F |
6.4.4 Taiwan Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.4.5 Taiwan Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Taiwan Phosphodiesterase (PDE) Inhibitors Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 Taiwan Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.5.3 Taiwan Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.5.4 Taiwan Phosphodiesterase (PDE) Inhibitors Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
7 Taiwan Phosphodiesterase (PDE) Inhibitors Market Import-Export Trade Statistics |
7.1 Taiwan Phosphodiesterase (PDE) Inhibitors Market Export to Major Countries |
7.2 Taiwan Phosphodiesterase (PDE) Inhibitors Market Imports from Major Countries |
8 Taiwan Phosphodiesterase (PDE) Inhibitors Market Key Performance Indicators |
8.1 Number of prescriptions for PDE inhibitors in Taiwan |
8.2 Patient adherence rates to PDE inhibitor treatment regimens |
8.3 Number of clinical trials and research studies on PDE inhibitors in Taiwan |
9 Taiwan Phosphodiesterase (PDE) Inhibitors Market - Opportunity Assessment |
9.1 Taiwan Phosphodiesterase (PDE) Inhibitors Market Opportunity Assessment, By Types, 2021 & 2031F |
9.2 Taiwan Phosphodiesterase (PDE) Inhibitors Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.3 Taiwan Phosphodiesterase (PDE) Inhibitors Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 Taiwan Phosphodiesterase (PDE) Inhibitors Market Opportunity Assessment, By End User, 2021 & 2031F |
9.5 Taiwan Phosphodiesterase (PDE) Inhibitors Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Taiwan Phosphodiesterase (PDE) Inhibitors Market - Competitive Landscape |
10.1 Taiwan Phosphodiesterase (PDE) Inhibitors Market Revenue Share, By Companies, 2024 |
10.2 Taiwan Phosphodiesterase (PDE) Inhibitors Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here